ALNA Allena Pharmaceuticals NASDAQ 22 Jan 2026: 252,311,606 shares, liquidity signal
ALNA stock moved on heavy volume intraday on 22 Jan 2026 after 252,311,606.00 shares changed hands on the NASDAQ in the United States. The ticker printed $0.075 at the trade print, a 3.16% intraday rise from the prior close, and a trading range between $0.06 and $0.15. That surge in activity coincides with market chatter about potential delisting and has amplified price swings for Allena Pharmaceuticals, Inc. (NASDAQ: ALNA). We look at the drivers, financials, technicals, and a concise forecast to frame the near-term opportunity and risk for ALNA stock.
Market action and intraday drivers for ALNA stock
Intraday trading on 22 Jan 2026 showed extreme liquidity in ALNA stock with 252,311,606.00 shares traded and a print at $0.075. The prior close was $0.07, and the stock opened at $0.06. High volume with a wide intraday range suggests short-term traders and stop-driven flows dominate the tape. Market commentary and listings risk statements have surfaced on public feeds and MarketBeat coverage, which likely intensified the move.
Fundamentals and financial metrics for Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a U.S. biotechnology company focused on oral enzyme therapies; the exchange is NASDAQ and reporting currency is USD. Key trailing metrics show EPS -0.64, PE -0.12, cash per share $0.92, book value per share $0.58, and current ratio 2.11. Revenue per share is effectively zero and market capitalization data is not meaningful in the public feed, indicating illiquid float and balance-sheet sensitivity.
Technical snapshot and trading range for ALNA stock
From a technical standpoint ALNA stock traded between $0.06 low and $0.15 high intraday, with a close near $0.075 on heightened volume. The gap between high and low suggests volatility above typical biotech small-cap moves. Short-term traders should watch prior intraday highs as resistance and $0.06 as immediate support. Limited 50- and 200-day moving averages in public data make trend assessment unreliable without longer, cleaner prints.
Meyka AI rates ALNA with a score out of 100 and analyst summary
Meyka AI rates ALNA with a score out of 100: Score 58.52 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects weak earnings history, positive short-term liquidity, modest cash per share, and listing risk. These grades are informational only and are not financial advice.
Risks, catalysts and sector context for ALNA stock
Primary risks for ALNA stock include potential NASDAQ delisting notices, limited trading float dynamics, and negative EPS trends. Catalysts that could move the tape include clinical updates for ALLN-346, capital raises, or formal NASDAQ communications. In the broader Healthcare and Biotechnology sector, investors have preferred larger-cap names; small biotech volatility and illiquidity tend to amplify both upside and downside for penny-priced stocks.
Price targets, forecasts and investment framing for ALNA stock
Realistic near-term price targets for ALNA stock reflect high uncertainty: base-case $0.12, bull $0.30, and bear $0.03. Meyka AI’s forecast model projects the base-case target above the current trade; these targets compare to the current price (USD 0.075) and imply scenario returns described below. Forecasts are model-based projections and not guarantees. For active traders, position sizing should account for outsized volatility and possible trading halts.
Final Thoughts
Key takeaways for ALNA stock on 22 Jan 2026: intraday liquidity spiked to 252,311,606.00 shares on NASDAQ and the stock printed $0.075, creating a volatile trading environment in the United States market. Allena Pharmaceuticals’ fundamentals show EPS -0.64, cash per share $0.92, and a current ratio 2.11, which provide some short-term runway but do not remove listing risk. Meyka AI’s forecast model projects a base-case target of $0.12 versus the current trade at USD 0.075, implying 60.00% upside in the base scenario; the bull and bear scenarios imply 300.00% upside and -60.00% downside respectively. These forecasts are model projections and not guarantees. Given the stock’s low price, wide intraday range, and potential delisting signals, our analysis frames ALNA stock as high-risk, short-term trading interest rather than a long-term core holding. For more real-time context and market signals, use Meyka AI as an AI-powered market analysis platform and consult primary filings and NASDAQ notices before trading.
FAQs
What caused the intraday spike in ALNA stock volume on 22 Jan 2026?
The intraday spike to 252,311,606.00 shares likely reflects a mix of speculation, short-term trading, and market chatter about potential NASDAQ delisting. Public coverage, including MarketBeat, increased attention and amplified volatility in ALNA
What are the key fundamentals to watch for ALNA stock?
Watch cash per share $0.92, EPS -0.64, book value per share $0.58, and NASDAQ listing status. Clinical progress for ALLN-346 and any capital raises will materially affect ALNA stock
What is Meyka AI’s forecast for ALNA stock?
Meyka AI’s forecast model projects a base-case $0.12, bull $0.30, and bear $0.03, compared with the current trade USD 0.075. Forecasts are model-based projections and not guarantees
Is ALNA stock suitable for long-term portfolios?
Given ALNA stock’s low price, negative EPS, and listing risk, it is generally unsuitable for conservative long-term portfolios. Only experienced investors who accept high volatility and illiquidity should consider small, speculative positions
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
